Next Phase Newsletter

By Sougato Das, President and COO, LSN

RESI Europe is one of the major pieces in the puzzle of how to stimulate biotech and life science investing in Europe. In addition to the largest investor partnering conference coming to Lisbon on March 23, the European Life Sciences Coalition (ELSC), a new alliance of major venture capital firms advocating for increased funding and policy support for Europe’s biotech sector, has launched. The coalition includes leading investors such as Novo Holdings, Sofinnova Partners, Forbion, and Omega Funds, representing a combined €24 billion in life sciences assets and involvement in more than 1,400 companies. It launched in association with Invest Europe, whose 650+ members manage 60% of European private equity and venture capital, totaling €1.25 trillion in assets. Alongside major initiatives like the European Innovation Council, whose funded companies enjoy 50% reimbursement for attending RESI Europe, the ELSC hopes to bring new energy to the entrepreneurial sector of life sciences. 

Despite Europe’s strong pharmaceutical presence—five of the world’s top 10 pharma companies by revenue are European—and the industry supporting 29 million EU jobs, the region struggles to scale and retain biotech and life science innovation. The coalition highlights several challenges: 

• Fragmented capital markets 

• Declining numbers of specialized VC firms 

• Regulatory hurdles 

• Limited access to growth capital 

Europe accounts for only 7% of global venture capital, compared to 63% for the U.S. and 14% for China. Fortunately, events like RESI Europe create a forum where nearly all of the firms representing the 7% are available for partnering, acting as a facilitator to stimulate European life science investment. The dire need for this is underscored by the fact that nearly all EU-based biotechs that went public last year chose to list outside the EU, highlighting concerns about capital flight. 

ELSC members joined the coalition to help reverse these trends, emphasizing the need for sustained funding from both public and private sources across all stages of life sciences development. Industry leaders argue that Europe must increase investment in innovative medicines and treatments, and create supportive policy frameworks and forums, like RESI Europe, or risk losing access to cutting-edge therapies. The ELSC aims to work with policymakers and leverage Invest Europe’s network to strengthen Europe’s ability to fund and scale biotech innovation domestically.

Tags: AI, art, books, business, economics, economy, education, entrepreneurship, finance, history, investing, photography, politics, religion, Research, startups, technology, travel, venture capital, writing

By Sougato Das, President and COO, LSN

After moderating innumerable virtual and in-person investor panels like those that will light up the stage at RESI Europe, one question comes from the audience repeatedly: What do investors like to see in a cap table? How can you ensure that the ownership of your company is structured so

1. There is enough to own for follow-on investors
2. It attractive to investors
3. You don’t get diluted too much
4. Shares, rights and vesting schedules that your shareholders have make sense for who they are
5. Underwriting and doing an IPO is easy when it’s time?

The answers to these questions are the bread and butter of investment bankers and investors.

LSN assembled panelists from J.P. Morgan and Mid Atlantic Bio Angels for a practical, founder-focused virtual session on Best Practices for Cap Table Management. This webinar will walk through the fundamentals every early-stage company needs to understand to make informed equity decisions and avoid costly mistakes down the road. Attendees will learn how to approach founder equity splits, navigate dilution, and confidently interpret SAFE notes. We’ll also explore how cap table structure directly impacts fundraising outcomes and why a well-designed stock option pool is critical for attracting and retaining top talent. This session is especially relevant for founders, CEOs, and CFOs who want to strengthen their financial strategy, prepare future rounds, and build a company that scales responsibly.

We’ve all heard the horror stories of founders who were diluted so much that they hardly made money after exiting. We’ve heard about non-investable companies that have great technology but are simply not financially attractive. We’ve heard about the difficult board member who had too many voting rights and slowed the company strategy. This webinar on cap table management will cover various use cases and explain why they do or do not work. There will be written Q&A during the webinar, so you can get all your questions answered.

Tags: AI, art, books, business, economics, economy, education, entrepreneurship, finance, history, investing, photography, politics, religion, Research, startups, technology, travel, venture capital, writing

By Sougato Das, President and COO, LSN

RESI JPM 2026 expands the opportunity to connect by adding Sunday partnering and event space, giving attendees an early start to JPM Week. With RESI JPM running Monday–Tuesday, Sunday provides a strategic window to schedule investor meetings, host receptions, or bring teams together while momentum is already building across San Francisco.

RESI JPM is the only JPM conference where 700+ investors actively providing seed to Series B funding attend, alongside in-licensors seeking preclinical through Phase 2 assets. For preclinical and clinical-stage biotech, medtech, diagnostic, digital health, and AI companies, RESI JPM remains the most efficient way to connect with aligned investors and strategic partners during JPM Week. Many companies schedule 10–20 meetings in a single day, making partnering the core of the RESI experience.

New Sunday Partnering Opportunities Added

Life Science Nation is announcing additional partnering slots on Sunday, January 11, hosted at the Marriott Marquis. These meetings take place ahead of the main conference and allow attendees to secure valuable investor conversations before calendars fill up.

The Sunday Partnering Slot sign-up form is available to RESI attendees, allowing registered participants to request meetings and plan their schedules in advance.

Start JPM Week with Purpose

This added day gives companies a head start to:

• Schedule investor or in-licensor meetings

• Connect with fellow RESI attendees

• Host private meetings or team gatherings

Located in the center of the JPM ecosystem, the Marriott Marquis offers a convenient and efficient setting to begin JPM Week with focused, high-value interactions.

With Sunday now in play, RESI JPM 2026 delivers more time, more access, and more opportunities to make meaningful connections before the week reaches full pace.

Tags: AI, art, books, business, economics, economy, education, entrepreneurship, finance, history, investing, photography, politics, religion, Research, startups, technology, travel, venture capital, writing

By Sougato Das, President and COO, LSN

The RESI 2026 Series continues Life Science Nation’s commitment to providing consistent, high-quality partnering opportunities for life science and healthcare innovators. Designed to connect startups with investors and strategic partners that align by sector, indication, and stage of development, each RESI conference offers a structured environment for founders navigating an increasingly competitive fundraising landscape.

Throughout the 2026 Series, attendees will find a familiar mix of investor panels, expert-led workshops, the Innovator’s Pitch Challenge, and a partnering system built to support targeted outreach and productive meetings. These elements work together to help companies strengthen their messaging, expand their networks, and identify capital sources that are the best fit for their technologies.

As scientific progress accelerates and capital deployment becomes more selective, the RESI 2026 Series serves as a reliable forum for global stakeholders to exchange insights, source opportunities, and build lasting relationships across the life science ecosystem.

Find registration information at RESIConference.com. If you are interested in RESI sponsorship, please contact us.

Tags: AI, art, books, business, economics, economy, education, entrepreneurship, finance, history, investing, photography, politics, religion, Research, startups, technology, travel, venture capital, writing

By Sougato Das, President and COO, LSN

RESI London 2025 will be the second year of the UK’s biggest life science investor conference. We expect 250 investors, ready to finance your company. The RESI partnering system allows you to schedule face to face meetings with each investor. See what last year’s attendees are saying!

Testimonials

Register RESI London by Friday, October 24 to save £200 on early bird rates!

Tags: AI, art, books, business, economics, economy, education, entrepreneurship, finance, history, investing, photography, politics, religion, Research, startups, technology, travel, venture capital, writing

By Sougato Das, President and COO, LSN

Many in the life sciences research community were spooked when PubMed went down temporarily in March after the Trump administration cut $4 billion in “indirect costs” that supported medical research. More recently, an ominous message appeared on PubMed: “Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed…” Many who use PubMed but not other government websites were probably panicked by this, but a quick look at clinicaltrials.gov, NIH Reporter and even NIH’s main site reveals the same message, while different versions of this message appear on the websites of HHS, CMS, etc.

Still, various EU governments have been quietly preparing for a PubMed shutdown by ensuring they will have a PubMed-alternative just in case. Of course, let’s be real: while they may be able to serve the existing content in PubMed, they will not be able to suddenly support the thousands of additional abstracts and articles added each day, along with MeSH tagging, journal selection, XML/JSON feeds, and other critical functions PubMed provides.

While PubMed is critical to nearly every life science researcher, even those with access to Web of Science, Embase, etc., it is especially critical to early-stage life science companies and investors. For basic research, competitive intelligence, due diligence and more, PubMed is indispensable for those without access to paid literature databases. PubMed is also an important source for pipeline database providers that investors and pharma use to find assets and perform CI.

The US government, for decades, has supplied a critical and reliable literature resource for worldwide audiences, both professional and non-professional alike. With the addition of the first and best clinical trial registry in 2000, continued funding for this resource is paramount for global biomedical research.

Tags: AI, art, books, business, economics, economy, education, entrepreneurship, finance, history, investing, photography, politics, religion, Research, startups, technology, travel, venture capital, writing